key: cord-0748056-09g45yed
authors: Kamal, Lina; Ramadan, Ahmed; Farraj, Suha; Bahig, Lydia; Ezzat, Sameera
title: The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
date: 2022-03-10
journal: Saudi Pharm J
DOI: 10.1016/j.jsps.2022.03.002
sha: 1c2815aa8101cf9e0f3a8929068e53d7892c694a
doc_id: 748056
cord_uid: 09g45yed

BACKGROUND: Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the virus spread, disease burden, hospitalization, and mortality. Until mid of 2021, the NIH treatment guideline declared no single oral therapy proven to treat mild to moderate cases. A new hope arose when a repurposed direct acting oral anti-viral agent “Molnupiravir” was shown to be effective in decreasing mortality and need for hospitalization in mild to moderate cases with relatively good safety profile; exhibiting a significant reduction in virus titers only after two days from administration. Molnupiravir recently granted the FDA emergency use authorization to treat mild to moderate COVID-19 patients with at least one risk factor for progression. METHODS: We performed a computer-based literature search of (PubMed, Science direct, MedRxiv, BioRxiv, ClinicalTrials.gov, ISRCTN, Cochrane COVID study register, EU registry, Clinical Trial Registry-India (CTRI)) till February 15(th), 2022. The following keywords were used in our search (“Molnupiravir ” or “NHC” or “EIDD-2807” or “MK-4482” or “EIDD-1931”). RESULTS: We identified from the initial search a total of 279 articles; 246 articles (BioRxiv and MedRxiv N=186, PubMed N=33, Science direct N=27) and 33 Clinical trials from the following registries (ISCTRN (N=1), Clinical trials.gov (N=6), CTRI (N=12), Cochrane (N=14)). Through screening phases, 21 records were removed as duplicates and 198 irrelevant records were also excluded. The included studies in this systematic review were (N=60) included 39 published papers and 21 clinical trials. After Manual addition (N=4), the qualitative assessment included (N=64). CONCLUSION: Based on the cumulative evidence from preclinical and clinical studies, Molnupiravir is proven to be well tolerated, direct acting oral anti-viral agent to halt the disease progression in mild to moderate COVID-19 cases; in terms of mortality and hospitalization rates.

As of February 27, 2022, severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the virus responsible for the debilitating coronavirus disease-2019 , has caused more than 435,099,899 confirmed infections and 5,964,788 deaths worldwide (Worldometer, 2022) . Both preclinical and clinical studies established association between SARS-CoV-2 RNA levels and the infectiousness of the host (Bullard et al., 2020; Cox et al., 2021; Kampen et al., 2021; Liu et al., 2020; Wölfel et al., 2020) . Thus, the urgent need for oral antiviral therapies was revealed as effective antiviral therapies would in turn allow to reduce disease progression and halt virus transmission. Massive efforts have been placed into the innovation of newly developed anti-viral agents and protective vaccines, the repurposing of already available anti-viral drugs was the suitable direction to control the COVID-19 pandemic situation (Pardi and Weissman, 2020) . There is an increasing list of antiviral agents extensively studied for their potential to be repurposed as an antiviral COVID-19 treatment (Milken Institute, 2022) . To-date, ritonavir-boosted nirmatrelvir, molnupiravir, sotrovimab, remdesivir, chloroquine or hydroxychloroquine, lopinavir/ritonavir, ivermectin and other HIV protease inhibitors have been listed as anti-viral agents for treatment of COVID-19 at different stages of the disease (NIH, 2022) .

Indeed, little of any anti-viral regimens has been established to reasonably impact the major clinical outcomes such as disease progression (ICU admission and need for mechanical ventilation) or mortality. Previously, the WHO investigated four promising antiviral agents to be repurposed for treatment of COVID-19 infections; however, according to the last report published for the mega study, the four regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay (WHO Solidarity Trial Consortium, 2021) . Similarly, agents like: sofosbuvir, favipiravir, oseltamivir, ribavirin, arbidol, nafamostat, nitazocanide and ivermectin was meticulously assessed as treatment options, however, most of these agents are still lacking established evidence to be appended to the list of approved antiviral agents (NIH, 2022) .

Molnupiravir is the prodrug of the ribonucleoside analog β-D-N4-hydroxycytidine (NHC), which undergoes chemical conversion in plasma into NHC and then into active 5′-triphosphate form through host kinases . The active form acts as a substrate for virally-encoded RNA-dependent RNA polymerase (RdRp), causing its antiviral effect via increasing mutations that occur with each viral replication cycle (Agostini et al., 2019; Painter et al., 2019 Painter et al., , 2021 . Through series of non-clinical studies, the drug exhibited antiviral activity against SARS-CoV-2 and other coronaviruses with a high barrier to resistance (Menachery et al., 2015; Sheahan et al., 2020; Wahl et al., 2021) . Molnupiravir was repurposed for treating mild to moderate COVID-19 infection through an expedited clinical development program. On December 23, 2021, molnupiravir was granted the FDA Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 patients, who are at high risk of progressing to severe disease, when other antiviral therapies are not accessible or clinically appropriate. The drug was also listed in the NIH treatment guidelines for COVID-19. However; the drug is indicated only when other treatment options are not available for patients. The guideline panel preferred other antiviral therapies because they showed higher efficacy in terms of lower hospitalization/death rate in the treated groups vs placebo (NIH, 2022) . Here, a systematic review on the cumulative evidence on molnupiravir safety and anti-viral activity is presented. Also, the review highlights a comparison between the current anti-viral agents listed to treat mild to moderate COVID-19 patients with risk for progression.

This systematic review complies with the preferred reporting items of the systematic review and meta-analysis (PRISMA) checklist (Moher et al., 2009) . All stages were verified to be compliant with the Cochrane Handbook of Systematic Review and Meta-Analysis (Higgins et al., 2019) .We performed a computer-based literature search of (PubMed, Science direct, MedRxiv, BioRxiv, ClinicalTrials.gov, ISRCTN, Cochrane COVID study register, EU registry, Clinical Trial Registry-India (CTRI)) till February 15 th , 2022. The following keywords were used in our search ("Molnupiravir " or "NHC" or "EIDD-2807 " or "MK-4482" or "EIDD-1931 . Articles assessed safety and/or the anti-viral activity of Molnupiravir were included. Books, reviews, articles published before 2020, duplicate articles, or articles not written in English were excluded. Manual addition of articles was conducted on three consecutive steps: firstly, by tracking references of the retrieved studies. Secondly, by tracking the articles that cited the retrieved studies and lastly, we did a google search to retrieve the most recent news on Molnupiravir . Four independent authors (AR, LB, LK and SF) reviewed the literature search results according to the presented inclusion and exclusion criteria.

The retrieved records were transferred to a Mendeley shared library to detect and remove duplicate articles using "check duplicates" function. Citations were checked for their title, authors, journal, and year for manual removal of duplicate articles. Title and abstract screening were performed by four independent authors (AR, LB, LK and SF) using Mendeley citation manager according to the stated inclusion criteria. Any disagreement was judged and solved by the last author (SE). For the phase of full-text screening, all articles were downloaded and reviewed for their eligibility. Further, the remaining references were exported to Excel file with key information for screening steps. The key information included: year of publication, authors, phase of assessment (preclinical and/or clinical), and main results. For the clinical trial registries, records were retrieved in CSV format when applicable, essential information of the clinical trials were retrieved and combined in one Excel sheet for further assessment. Clinical trials registered in multiple databases were manually removed. Finally, the decision to include or exclude articles for qualitative analysis had to be agreed upon by the four reviewers (AR, LB, LK and SF) to pass through. In case of any disagreements, the last author (SE) was requested to give a final decision.

We identified from the initial search a total of 279 articles; 246 of them from databases (BioRxiv and MedRxiv N=186, PubMed N=33, Science direct N=27) and 33 Clinical trials from the following registries (ISCTRN (N=1), Clinical trials.gov (N=6), CTRI (N=12), Cochrane (N=14)).

After reviewing abstracts, removing 21 records as duplicates, and excluding 198 irrelevant records, 

The COVID-19 RNA-dependent RNA polymerase (RdRp) complex was synthetically produced in two separated studies with compatible results to investigate the mechanism of Molnupiravir -induced COVID-19 mutagenesis. This mechanism was set in a two-step model. The Molnupiravir -induced coronavirus RNA mutagenesis like the suggested mutagenesis mode of action of Favipiravir but not the one of Remdesivir, which undertakes its action in the first step of the model by impairs RdRp progression (Gordon et al., 2021; Kabinger et al., 2021) . The differences in the fighting mechanisms between these two antiviral drugs were supported by Sheahan et al. when they found that error rate (no. of mutations/10,000 bases) is the same in treated viruses by remdesivir and untreated viruses whether the error rate was significantly increased in a dose-dependent manner when Molnupiravir was used (Sheahan et al., 2020) . Wang et al. found that RdRp of SARS-CoV-2 can utilize nucleoside diphosphate (NDP) as a substrate in RNA syntheses as if it was a nucleoside triphosphate (NTP) with the same efficiency which is a unique feature of SARS-CoV-2 RdRP. Moreover, they approved that this fact also applied on β-d-N4hydroxycytidine (NHC) diphosphate, called MDP, which used as a substrate by RdRp to be another active form of Molnupiravir as NHC triphosphate (MTP) .

The type of mutations produced by using Molnupiravir was studied computationally. Jena and her colleagues found that the binding between Molnupiravir nucleotide analogue and G base was more stable than the other analogues bases (Remdesivir, Galidesivir, Favipiravir, and Ribavirin) when they pair with normal bases. It is even more stable than the typical G:C pair and give similar structural to its Watson-Crick structure. This propriety can explain the escaping of exonuclease proofreading during the replication of the virus (Jena, 2020) . This result confirmed using a SARS-CoV replicon that lacks of exonuclease where Molnupiravir activity did not significantly affect (Lan et al., 2021) . In another in-silico study, Padhi et al. found that the binding site in nonstructural protein 12 (nsp12) of SARS-CoV-2 is relatively immune to be mutant by on SARS-CoV-2-infected hamsters, higher accumulation of mutations especially in C-to-T and Gto-A transitions were found in Molnupiravir treatment group in a dose dependent manner (Abdelnabi et al., 2021a) .

Several preclinical studies measured the mutagenesis effect of using Molnupiravir on host DNA. Sheahan et al. didn't find any accumulation of mutations when they tested the effect of Molnupiravir on mice lung tissues infected by MERS-CoV. They concluded that using Molnupiravir for virus treatment can't incorporate into host cell DNA and thus can't induce mutations in it because ribonucleotides are removed from eukaryotic cell DNA efficiently (Sheahan et al., 2020) . A comparison between the mutagenicity of Molnupiravir , Favipiravir and Ribavirin was done in vitro in another study; Molnupiravir showed resistance in the studied colonies in a dose-dependent manner but did not inhibit cell growth. Favipiravir showed a modest yet significant increase in the number of resistant colonies but also without showing an inhibition in the cell growth. While ribavirin showed little to no resistant activity but inhibited cell growth.

They suggested that the reason behind the resistant effect of Molnupiravir on the cell can be presumably caused by the conversion to its intermediate DNA precursor that produced by normal metabolic pathway (Zhou et al., 2021a) .

Molnupiravir antioxidant properties was studied by Martínez. In general, free radicals can be hunted by electron donor or electron acceptor molecules and thus oxidative stress can be prevented. Most antiviral drugs like Remdesivir and Ribavirin are electron donors which can affect viral infection by reducing molecules necessary for essential steps in its life cycle. This can also be a side effect for the drug because they reduce other essential molecules for patient life. The same principal can be applied if the antiviral drug was an electron acceptor which can oxidize molecules that essential for both virus and human. Molnupiravir is an electron acceptor but not a good one, which means it is not an effective oxidant. Therefore, it is side effect can be minimum from this viewpoint when be used against COVID-19 (Martínez, 2021) .

Number of in vitro and in vivo studies done to investigate the activity of Molnupiravir against different SARS-CoV-2 variant of concern (VoC), involving alpha (B.1.1.7), beta (B.1.351), gamma (P.1.), delta (B.1.617.2), omicron (B.1.1.529) and the origin lineage A (Wuhan strain).

These studies agreed that the inhibition of the virus by Molnupiravir was similar between all VoC (Abdelnabi et al., 2021a; Bojkova et al., 2022; Lieber et al., 2022; Prince et al., 2021; Rosales et al., 2022; Vangeel et al., 2022) . In one of these studies, the result of this reduction remained equivalent when Human ACE-2 A549 cells was treated with Molnupiravir prior-infection, at the infection, after two, four-or 24-hours post-infection. When the treatment was given after two days from the infection, the activity of the drug was reduced for all tested CoV which could justify why the using of Molnupiravir was stopped in hospitalized patients and just licensed for the mildmoderate outpatients (Prince et al., 2021) . In Syrian hamsters, there was also a comparable significant improvement in the pathology of lung with different VoC infections (Abdelnabi et al., 2021a) . Also, they found in ferrets models a consistent of VOC shedding from the upper respiratory which avoided viral transmission. However, not the equal shedding found in the lungs of treated dwarf hamsters which was VOC-dependently although all the animals completely cured regardless the injected VoC. Surprisingly, Omicron showed sex dependent in the response to treatment which the reduction in male was overall better than females without seeing this difference with VOC gamma or delta (Lieber et al., 2022) .

The similarity of viral load reduction between the different VoC of SARS-CoV-2 when treated with Molnupiravir was expected because the drug is targeting the replication prosses of the virus which depends on highly conserve virus protein with minimum missense mutations (Bojkova et al., 2022; Vangeel et al., 2022) .

A combination of Molnupiravir and Favipiravir was obtained by Syrian hamsters directly before infected them with SARS-CoV-2. A higher reduction of viral titer was observed for the combo-treatment compared to mono-treatment. Abdelnabi et al. explained Molnupiravir or any of these drugs. However, that wasn't the result with remdesivir, or Overall, all the combinations presented with no detectable infectious virus at 72hour prior infection (Jonsdottir et al., 2022) .

Phase 1 studies on molnupiravir were conducted when preliminary data were submitted on the activity of the promising drug. In a study testing human safety, tolerability, and Pharmacokinetics of Molnupiravir , Molnupiravir was well absorbed in doses from 50-1600 mg, and the parent Ribonucleoside analogue EID-1931 was detected in plasma in a linear, dose proportional manner. It was also observed that absorption rate is lower in the fed state and took longer time (lower Tmax and Cmax); yet the extent of absorption (AUC inf.) wasn't significantly different between fed state and fasted state. Molnupiravir showed safety and tolerability at a range from 50 to 800 mg dose when taken twice daily for 5-5.5 days or when taken as single dose up to 1600 mg in several trials. There was no accumulation reported in the multiple ascending dose group; a trace amount of Molnupiravir was found in urine due to EID-1931 metabolism by the kidneys into Cytidine and Uridine. The drug was found to be well tolerated and the reported adverse events were mild, non-serious, rapidly resolved and didn't cause drug discontinuation. The most common observed adverse events reported were headache with the single ascending dose, diarrhea in the multiple ascending doses, also those adverse events were reported in placebo group; headache (18.8% placebo in comparison to 12.5% Molnupiravir ) and diarrhea (7.1% in both placebo and Molnupiravir ). Also, there were no serious adverse events or dose-related events in the labs, clinical assessment, vital signs, and ECG of subjects . In another Phase 1 controlled trial [NCT04392219] on healthy volunteers, subjects were administered doses of 300, 600 and 800 mg of Molnupiravir . Twice daily dose of 800 mg of Molnupiravir was found to be safe and tolerable in participants with SARS CoV-2 infection in the AGILE trial

[NCT04746183] . All AEs reported were mild (≤ grade 2 severity); diarrhea, nausea, cough, loss of smell or taste and flu like symptoms were reported and rapidly. Hence, A remarkable advantage of Molnupiravir over other injectable antiviral drugs is its oral availability, possibility of widespread global application as well as a favorable safety profile and high tolerability Rosenke et al., 2021) .

Molnupiravir in the treatment of participants with SARS-CoV-2 infection who showed significant viral load reduction at day 5 from administration with significantly higher reduction in the 800 mg (Table 1) . with molnupiravir than with placebo. And the investigators considered all the deaths to be Covid-19-related (Table 2) . Also, MOVe-OUT study showed WHO Clinical Progression Scale benefits with molnupiravir over placebo (Jayk Bernal et al., 2021) . The difference between the interim and the all-randomized analyses' results are summarized in Table 2 . Many factors were likely to be correlated with this difference; of them, there were more participants with low viral load at baseline (in whom there is less virologic effect) at the time of the all-randomized sample than at the time of the interim analysis. In addition, newly enrolling countries, were included in all-randomized sample which may also have affected hospitalization rates as part of the primary outcome. No mortality was reported in both groups

Molnupiravir showed potent antiviral activity against SARS-CoV-2 virus (Kabinger et al., 2021; Zhou et al., 2021b) . The drug is also expected to be active against the Omicron VOC, although in vitro and in vivo data are currently limited (Vangeel et al., 2022) . Nonetheless, its mutagenic antiviral activity speculated a risk for being metabolized and incorporated into the human DNA, leading to consequent mutations. Further, the mutagenicity of molnupiravir was investigated in a study utilized a rodent mutagenicity assay; the study showed no evidence for mutagenicity. Based on the conducted research on genotoxicity of the drug, the FDA concluded that molnupiravir has a low risk for genotoxicity on short treatment course of 5 days (FDA, 2021a). (FDA, 2021b) . Thus, they are challenged with a relatively small effect size; as probability for disease progression to cause hospitalization or mortality doesn't exceed 5-10% among mild to moderate cases (Mahendra et al., 2021) . Till mid of 2021, the NIH COVID-19 treatment guideline was stating "No therapy has been proven to be beneficial in outpatients with mild to moderate COVID-19 patients who are not at high risk for disease progression". At this time, only remdesivir was granted EUA by FDA since it was reported to reduce recovery time in patients suffering from severe COVID-19

infections; however, the application of remdesivir was limited for that it's only administered via intravenous route in a hospital setting. Currently, despite there is an increasing list of antiviral drugs for treatment of mild to moderate cases with risk for progression, no therapy has been yet proven to treat mild to moderate cases with no risk for progression. This may be explained by the very low risk for progression for this population.

Overall, despite it is proved that oral molnupiravir is effective for the treatment of COVID-19, without evident safety concerns, when initiated within 5 days after the onset of signs or symptoms in non-hospitalized unvaccinated adults, the FDA and NIH COVID-19 treatment guideline both recommended using molnupiravir only when ritonavir-boosted nirmatrelvir, sotrovimab, and remdesivir are not available (NIH, 2022) . Ritonavir-boosted nirmatrelvir was also granted the FDA EUA on December 22, 2021 (FDA, 2021c), for treatment of mild to moderate cases with risk for progression. The EPIC-HR trial showed that starting ritonavir-boosted nirmatrelvir, within 5 days of symptom onset, in adults with mild to moderate COVID-19 reduced the risk of hospitalization/death by 89% through Day 28 (Hammond et al., 2022) . This significant reduction in the primary efficacy endpoint was comparable to that reported for sotrovimab (85% relative reduction) (Gupta et al., 2021) and remdesivir (87% relative reduction) (Gottlieb et al., 2022) , and greater than the finally reported efficacy for molnupiravir (30% relative reduction) (Jayk Bernal et al., 2021) .

Currently, molnupiravir is being investigated for protection against COVID-19 infection in a multi-center clinical trial [Move-ahead, NCT04939428]; where the target population are subjects who lives in a household with a person recently confirmed with COVID-19 infection. It also worth noting that molnupiravir was tagged for successful combination with favipiravir in the clinical settings; anticipating a synergistic and more potent antiviral activity against COVID-19 (Abdelnabi et al., 2021b) . These findings may be the basis for large clinical studies to test the efficacy of the proposed combination of Molnupiravir/Favipiravir for treatment of COVID-19.

To the best of our knowledge, this is the first systematic review that thoroughly cover both preclinical and clinical studies on Molnupiravir as an antiviral therapy to treat COVID-19

infections. However, lack of data from clinical trials made it a qualitative review without a quantitative compiling of the clinical evidence through meta-analysis.

The conducted preclinical and clinical studies confirm the efficacy and safety of Molnupiravir as an antiviral therapy to treat mild to moderate COVID-19 infections with high risk for progression.

Nonetheless, as for all repurposed antiviral drugs, more data from clinical trials is still required to determine its exact efficacy and tolerability; especially for special population. molnupiravir is currently being investigated for the potential use in post-exposure prophylaxis against COVID-19

and tagged for possible combinations with other antivirals; which if found to be effective, it would be a new turning in the COVID-19 pandemic situation.

Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Small-Molecule Antiviral β-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Emergency Use Authorization Letter for Molnupiravir [WWW Document

Fact sheet for healthcare providers: emergency use authorization for molnupiravir

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention

Fact sheet for healthcare providers: emergency use authorization for Paxlovid

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India

Cochrane handbook for systematic reviews of interventions, Cochrane Handbook for Systematic Reviews of Interventions

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Eijk, A.A. van der, 2021. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication

SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19

Viral dynamics in mild and severe cases of COVID-19

Predictors of mortality in patients with severe COVID-19 pneumonia -a retrospective study

Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Milken Institute's COVID-19 Treatment and Vaccine Tracker [WWW Document

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Antiviral Therapy | COVID-19 Treatment Guidelines [WWW Document

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance. iScience 24, 101992

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2

Development of vaccines and antivirals for combating viral pandemics

Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

27 generic manufacturers sign agreements with MPP to produce low-cost versions of molnupiravir

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis

Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Virological assessment of hospitalized patients with COVID-2019

Worldometer, 2022. COVID Live -Coronavirus Statistics -Worldometer

Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

(NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells